Surprisingly, we found that treatment with the BACE1 inhibitor AZD3293 increased the spiking in these two different AD mouse models: in Bace1fl/fl/5xFAD mice (456.03 ± 128.64 spikes, n = 6, p = 0.42) and in APP KI mice (207.94 ± 43.07 spikes, n = 6, p < 0.05), compared with age-matched Bace1fl/fl/5xFAD and APP KI mice without AZD3293 treatment, respectively (Fig. 1E). This evidence concerns the gene APP and Alzheimer disease.